NCT03174535View on ClinicalTrials.gov

Risk Assessment Model for Ischemic Stroke Endpoint Events

CompletedOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2019

Conditions
Ischemic Stroke
Interventions
DRUG

Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.

The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.

Trial Locations (1)

100700

Yanming Xie, Beijing

All Listed Sponsors
lead

China Academy of Chinese Medical Sciences

OTHER

NCT03174535 - Risk Assessment Model for Ischemic Stroke Endpoint Events | Biotech Hunter | Biotech Hunter